Overview

Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)

Status:
Completed

Trial end date:
2015-12-15

Target enrollment:
0

Participant gender:
All

Summary

This is a study of the efficacy of sitagliptin and glibenclamide in a short-term treatment on the glucose variability using continuous glucose monitoring (CGM) in Japanese participants with type 2 diabetes mellitus (T2DM). The primary hypothesis is that treatment with sitagliptin will be superior to treatment with glibenclamide in the change from baseline in mean amplitude of glycemic excursions (MAGE) through continuous glucose monitoring (CGM) after 13 days of treatment.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Glyburide
Sitagliptin Phosphate

Criteria

Inclusion Criteria:

- Japanese participants with a diagnosis of Type 2 diabetes mellitus

Exclusion Criteria:

- History of Type 1 diabetes mellitus or ketoacidosis

- History of insulin or thiazolidinedione (including fixed-dose drug combinations
containing one of these drugs) in the 12 weeks before study participation